# **Supplementary Material: Assessing eligibility for lung cancer screening:** Parsimonious multi-country ensemble machine learning models for lung cancer

prediction

# Contents

r arteipart new aragiane	3
eFigure 1: Flow diagram of UK Biobank participants	3
eFigure 2: Flow diagram of NLST participants included	3
eFigure 3: Flow diagram of PLCO participants included	4
Variable recoding, missing data, and multiple imputation	5
UK Biobank: Recoding smoking variables	5
UK Biobank: Missing data & multiple imputation	5
eTable 1: Distribution of complete data across smoking variables in our development cohort (UK Biobank)	5
eFigure 4: Nelson-Aalen curves of probability of (a) developing and (b) dying from lun cancer amongst ever-smokers with different patterns of missing smoking data in the l Biobank	ig JK 6
eFigure 5: Nelson-Aalen curves of probability of developing (a) and dying from (b) lun cancer amongst non-occasional ever-smokers not missing smoking intensity and dura in the UK Biobank	g ation 6
eFigure 6: Nelson-Aalen curves of probability of developing (a) and dying from (b) lun cancer amongst ever-smokers with smoking intensity and duration, ever-smokers mis smoking intensity and duration, and never-smokers in the UK Biobank	g sing 7
UK Biobank Imputation	7
NLST & PLCO: Missing data and multiple imputation	7
Model development	8
Details of UCL-D	8
eFigure 7: The UCL-D ensemble and constituent pipelines (predicted outcome is five	vear
risk of death from lung cancer).	8
eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorit in UCL-D	8 hms 9
eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorit in UCL-D	hms 9
<ul> <li>eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorit in UCL-D</li> <li>Details of UCL-I</li> <li>eFigure 8: Details of the UCL-I ensemble (predicted outcome is five-year risk of developing lung cancer).</li> </ul>	hms 9 9
<ul> <li>eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorit in UCL-D.</li> <li>Details of UCL-I</li> <li>eFigure 8: Details of the UCL-I ensemble (predicted outcome is five-year risk of developing lung cancer)</li> <li>eTable 3: Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine lear algorithms in UCL-I.</li> </ul>	8 hms 9 9 9 9 ning 10
<ul> <li>eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorit in UCL-D</li> <li>Details of UCL-I</li> <li>eFigure 8: Details of the UCL-I ensemble (predicted outcome is five-year risk of developing lung cancer).</li> <li>eTable 3: Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine lear algorithms in UCL-I</li> </ul>	,8 hms 9 9 9 ning 10 10
<ul> <li>Figure 1: The COL D checking cancer is a constituent pipelines (predicted outcome is inversion of the transmission of transmission of transmission of transmission of transmission of the transmission of the transmission of the transmission of tra</li></ul>	,8 hms 9 9 9 ning 10 10 11
<ul> <li>risk of death from lung cancer).</li> <li>eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorit in UCL-D.</li> <li>Details of UCL-I</li> <li>eFigure 8: Details of the UCL-I ensemble (predicted outcome is five-year risk of developing lung cancer).</li> <li>eTable 3: Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine lear algorithms in UCL-I.</li> <li>Cox models.</li> <li>eTable 4: Predictors used in comparator prognostic models.</li> </ul>	, youn ,
eTable 3: Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine learning algorit eTable 3: Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine lear eFigure 8: Details of the UCL-I ensemble (predicted outcome is five-year risk of developing lung cancer) eTable 3: Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine lear algorithms in UCL-I Cox models eTable 4: Predictors used in comparator prognostic models Variable importance and interactions Supplementary Results	, year ,
eTable 4: Predictors used in comparator prognostic models. eTable 4: Predictors used in comparator prognostic models. Pable 5: Descriptive characteristics of UK Biobank ever-smokers by outcome.	<pre>hms hms999 ning1011121314</pre>

eTable 7: Descriptive characteristics of PLCO radiography arm ever-smokers by outcome	8
eTable 8: Descriptive characteristics of all PLCO ever-smokers by outcome	0
eTable 9: Outcomes by dataset22	2
eTable 10: Discrimination of UCL-D, Cox models, and the constrained LCDRAT, LCRAT, and PLCOm2012 models23	3
eTable 11: Brier scores in UK Biobank and PLCO radiography arm24	4
eTable 12: Model sensitivity and sensitivity at specified risk thresholds in the PLCO dataset	6
eFigure 9: Outcomes by eligibility for either UCL-D or UCL-I, but not both UCL models 2	7
eFigure 10: Net benefit of models in the UK Biobank28	8
Full Models	9
UCLFull-D	9
UCLFull-I	9
eTable 13: Discriminative accuracy (AUC) in the whole PLCO cohort	0
eTable 14: Overall performance (Brier scores) in the whole PLCO cohort	1
eFigure 12: Calibration curves for UCL models in the full PLCO cohort	3
eFigure 13: Net benefit of UCL models in the full PLCO cohort	4
eTable 15: Sensitivity and sensitivity of UCLFull-D and UCLFull-I at specified risk thresholds in the PLCO dataset	5
References	6

### Authors and affiliations:

Thomas Callender<sup>1</sup>, Fergus Imrie<sup>2</sup>, Bogdan Cebere<sup>3</sup>, Nora Pashayan<sup>4</sup>, Neal Navani<sup>1</sup>, Mihaela van der Schaar<sup>3,5,6\*</sup>, Sam M Janes<sup>1\*</sup>

<sup>1</sup> Department of Respiratory Medicine, 5 University Street, University College London <sup>2</sup> Department of Electrical and Computer Engineering, University of California, Los Angeles <sup>3</sup> Department of Applied Mathematics and Theoretical Physics, University of Cambridge <sup>4</sup> Department of Applied Health Research, 1-19 Torrington Place, University College London <sup>5</sup> Cambridge Centre for Al in Medicine, University of Cambridge <sup>6</sup> Alan Turing Institute

\*Joint senior authors

### Participant flow diagrams



eFigure 1: Flow diagram of UK Biobank participants

From the UK Biobank, we included 216,714 ever-smoking individuals without a known diagnosis of lung cancer (ICD-10 codes C33-C34) aged 40 or more at baseline (eFigure 1). The UK Biobank is a prospective cohort of men and women recruited between 2006-2010 from 22 assessment centres across the UK which combines phenotypical data with ongoing linkage to national cancer and mortality registries.<sup>1</sup> During this timeframe, the UK has not had a systematic screening programme for lung cancer.



eFigure 2: Flow diagram of NLST participants included

From the NLST, we included the 26,616 individuals without a prior history of lung cancer who had been randomised to the control arm of the trial (eFigure 2). The NLST was a

randomised controlled trial of lung cancer screening comparing computed tomography (CT) against chest radiography in 33 US centres between 2002-2004 with follow-up through 2009.<sup>2</sup> Participation in the NLST was restricted to those considered at high risk of developing lung cancer: a 30 pack-year smoking history and, if a former smoker, to have quit within 15 years of enrolment.<sup>2</sup>



eFigure 3: Flow diagram of PLCO participants included

The PLCO was a randomised controlled trial of lung cancer screening with chest radiography compared to a non-interventional control that took place between 1993-2001 in 10 US centres.<sup>3</sup>

### Variable recoding, missing data, and multiple imputation

#### UK Biobank: Recoding smoking variables

To determine smoking status in the UK Biobank, we used their self-recorded smoking status (field 20116). We then re-coded the 9,010 participants who had declared (field 1249) they had never tried smoking, had smoked only once or twice, or less than 100 cigarettes in their lifetime (field 2644) to non-smokers. The final numbers by smoking status were: 282,428 never smokers, 165,714 former smokers and 52,000 current smokers.

#### UK Biobank: Missing data & multiple imputation

As the most influential risk factor for lung cancer, we specifically analysed patterns of missingness in smoking variables. Three smoking variables were key: age start smoking, age stop smoking, and smoking intensity (number of cigarettes smoked per day). Based on these three variables, variables such as smoking duration and pack-years are calculated.

In the UK Biobank development cohort, just over two-thirds of all participants (68.9%), and over five-sixths of those who developed lung cancer (86.3%) and of those who died from lung cancer (86.8%) during follow-up had complete data across all included predictors (eTable 1). However, we noted that missing all three smoking variables was the most common pattern amongst all participants, occurring in nearly one-quarter of ever-smokers in our development dataset (22.6%).

Variables missing	All participants, n=216,714 (n, %)	Developed lung cancer, n=3,449 (n, %)	Died from lung cancer, n=2,137 (n, %)
Complete data	149,328 (68.91)	2,977 (86.31)	1,854 (86.76)
1	10,264 (4.74)	228 (6.61)	137 (6.41)
2	8,074 (3.73)	56 (1.62)	35 (1.64)
3	49,048 (22.63)	188 (5.45)	111 (5.19)

**eTable 1:** Distribution of complete data across smoking variables in our development cohort (UK Biobank)

Within the context of prediction modelling, our interest is the relationship between missingness in a variable and the outcome – the informativeness of missingness – and the impact this has on predictive performance<sup>4</sup>. Amongst those with an outcome of interest, the most common pattern was to be missing one variable; missing one variable was not associated with a higher cumulative risk of developing lung cancer (log-rank test p = 0.07) or dying from lung cancer (log-rank test p = 0.31). By contrast, as shown in eFigure 5, missing three variables - the next most common pattern seen amongst those with an outcome of interest - was associated with a different risk of an outcome relative to those with complete data (log-rank test p < 0.001).



**eFigure 4:** Nelson-Aalen curves of probability of (a) developing and (b) dying from lung cancer amongst ever-smokers with different patterns of missing smoking data in the UK Biobank

Reviewing those participants who were missing all three key smoking variables, nearly all (99.9%, n=49,030) were recorded as former smokers who had only smoked occasionally (UK Biobank fields 20116 & 1249). These individuals were not questioned about the number of cigarettes they smoked per day. On removing these participants from analysis, the relationship between missingness and the outcomes of interest inverted (p < 0.001 for risk of developing or dying from lung cancer, eFigure 6).



**eFigure 5:** Nelson-Aalen curves of probability of developing (a) and dying from (b) lung cancer amongst non-occasional ever-smokers not missing smoking intensity and duration in the UK Biobank

However, the former occasional smokers themselves showed different outcome profiles to both current smokers recorded to only smoke occasionally and non-smokers (eFigure 7). We therefore included them in our analyses.



**eFigure 6:** Nelson-Aalen curves of probability of developing (a) and dying from (b) lung cancer amongst ever-smokers with smoking intensity and duration, ever-smokers missing smoking intensity and duration, and never-smokers in the UK Biobank

#### **UK Biobank Imputation**

We generated 10 imputed datasets using multiple imputation by chained equations (MICE) and a tree-based Gradient Boosting imputation model (LightGBM) to avoid assumptions about statistical relationships between the variables, implemented with the Python package miceforest.<sup>5</sup> For each candidate predictor with missing data, a model was fit that consisted of both a common pool of candidate variables and lung cancer outcomes as well as a bespoke set of predictors that were specifically correlated with missingness in the variable of interest.<sup>6</sup>

To account for the systematic difference between former 'occasional' smokers missing cigarettes smoked per day and others, we imputed this number by taking a random draw from a *Gamma*(1.5626, 6.4) distribution. This equates to a median of 8 cigarettes smoked per *month* (interquartile range: 4-14, 2.5th and 97.5th centile: 0.8 and 31). We repeated this for each of the 10 imputed datasets.

Models were developed using a single imputed dataset as there are no established methods for pooling machine learning model hyperparameters between imputed datasets. However, to assess model performance, we pooled all ten imputed datasets using Rubin's rules.

### NLST & PLCO: Missing data and multiple imputation

Overall missingness was <1% for all relevant variables in both the NLST and PLCO datasets. For congruence when creating a multi-country dataset for model development, we created 10 imputed NLST datasets. Given the low level of missingness, we generated five imputed PLCO datasets. In both cases we used multiple imputation by chained equations with predictive mean matching, implemented as described above.

### Model development

We fit models using AutoPrognosis,<sup>7,8</sup> and for comparison and model validation with Cox proportional hazards regression.

In this analysis, AutoPrognosis searched for optimal pipelines – where each pipeline consists of three stages: dimensionality reduction, predictor pre-processing, and the model algorithm – from 252 potential combinations. The following algorithms were considered:

- Dimensionality reduction: none, variance thresholding, principal component analysis, independent component analysis.
- Predictor pre-processing: none, normalisation, polynomial interactions between features, scaling each predictor using its maximum absolute value, min-max scaling, uniform transformation, standardisation.
- Modelling algorithms: logistic regression, linear discriminant analysis, quadratic discriminant analysis, bagging, random forests, Adaboost<sup>9–11</sup>, CatBoost<sup>12,13</sup>, LightGBM<sup>14,15</sup>, XGBoost<sup>16,17</sup>.

AutoPrognosis uses Bayesian optimisation for pipeline selection,<sup>7</sup> whilst the hyperparameters of each modelling algorithm trialled were tuned using Optuna.<sup>18</sup> Ensembles are generated using both stacking and aggregating methods from the Python package combo<sup>19</sup> and by Bayesian model averaging.<sup>7</sup> All pipelines and ensembles were trained using five-fold cross-validation to maximise the area under the receiver operating curve (AUC), with the highest performing ensemble selected. We considered ensembles that consisted of up to four different modelling pipelines. In other words, should a single pipeline, for example one involving no dimensionality reduction, predictor standardisation, and subsequently the machine learning algorithm LightGBM, have had greater discrimination than an ensemble of several pipelines, this would have been selected.

### **Details of UCL-D**

UCL-D is an ensemble of four modelling pipelines predicting the five-year risk of dying from lung cancer. The final ensemble, constituent pipelines, and the weighting assigned to each pipeline are shown in eFigure 7. The tuned hyperparameters for the AdaBoost and LightGBM algorithms are shown in eTable 2.



**eFigure 7:** The UCL-D ensemble and constituent pipelines (predicted outcome is five-year risk of death from lung cancer).

Algorithm	Hyperparameter	Value
AdaBoost <sup>9-11</sup>	n_estimators	10
Auabuusi	learning_rate	0.1
	boosting_type	'gbdt'
	learning_rate	0.1
	max_depth	6
	reg_alpha	9.65x10-6
LightGBM <sup>14,15</sup>	reg_lambda	1.07x10-8
	colsample_by_tree	0.48
	subsample	0.61
	num_leaves	3
	min_child_samples	139

eTable 2: Hyperparameters for the AdaBoost and LightGBM machine learning algorithms in UCL-D

### **Details of UCL-I**

UCL-I is also an ensemble of four modelling pipelines that instead predicts the five-year risk of lung cancer occurrence. Details of the ensemble and tuned hyperparameters for the constituent machine learning algorithms are shown in eFigure 8 and eTable 3.



eFigure 8: Details of the UCL-I ensemble (predicted outcome is five-year risk of developing lung cancer).

Algorithm	Hyperparameter	Value
AdaBoost <sup>9-11</sup>	n_estimators	10
Auaboosi	learning_rate	0.1
	boosting_type	'gbdt'
	learning_rate	0.1
	max_depth	6
LightGBM <sup>14,15</sup>	reg_alpha	0.036
	reg_lambda	9.08x10-5
	colsample_by_tree	0.11
	subsample	0.11
	num_leaves	3
	min_child_samples	23
	learning_rate	0.039
	depth	7
CatBoost <sup>12,13</sup>	l2_leaf_reg	554.36
	random_strength	1.303
	grow_policy	"Lossguide"

**eTable 3:** Hyperparameters for the AdaBoost, LightGBM, and CatBoost machine learning algorithms in UCL-I

#### Cox models

We developed Cox models using the survival<sup>20</sup> and rms<sup>21</sup> packages in R. To account for non-linear relationships between age, smoking duration, pack-years and lung cancer (death), we used restricted cubic splines modelled with three knots. In common with both Tammemagi,<sup>22</sup> Katki,<sup>23</sup> and their colleagues, we found that no interactions between the three variables were significant within a Cox framework. Further, Cox models without including interaction terms had lower Akaike Information Criteria (AIC) values. We present the c-index for models both with and without interactions in the Appendix results.

Model	Predictors
UCL-D & UCL-I	<ol> <li>Age</li> <li>Smoking duration (years)</li> <li>Pack-years<sup>a</sup></li> </ol>
PLCOm2012 <sup>22</sup>	<ol> <li>Age</li> <li>Smoking status</li> <li>Smoking duration (years)</li> <li>Smoking intensity (number of cigarettes per day)</li> <li>Quit-years (if former smoker)</li> <li>Ethnicity (White, Black, Hispanic, Asian, American Indian or Alaskan Native, Native Hawaiian or Pacific Islander)</li> <li>Highest qualification</li> <li>Body-mass index</li> <li>Chronic obstructive pulmonary disease (COPD)</li> <li>Personal history of cancer</li> <li>Family history of lung cancer</li> </ol>
LCRAT & LCDRAT <sup>23</sup>	<ol> <li>Age</li> <li>Sex</li> <li>Ethnicity (White non-hispanic, Black non-Hispanic, Hispanic, Asian or other)</li> <li>Highest qualification</li> <li>Body-mass index</li> <li>Smoking duration (years)</li> <li>Smoking intensity (number of cigarettes per day)</li> <li>Quit-years (if former smoker)</li> <li>Pack-years</li> <li>History of emphysema</li> <li>Family history of lung cancer</li> </ol>
LLP versions 2 & 3 <sup>24</sup>	<ol> <li>Age</li> <li>Sex</li> <li>Smoking duration (years)</li> <li>Pneumonia,</li> <li>Asthma,</li> <li>Bronchitis, emphysema, or COPD</li> <li>Tuberculosis</li> <li>Asbestos exposure</li> <li>Personal history of cancer</li> <li>Family history of lung cancer (none, before age 60, after age 70)</li> </ol>

eTable 4: Predictors used in comparator prognostic models

<sup>&</sup>lt;sup>a</sup>Pack-years combine smoking duration with the number of cigarettes smoked, with one pack-year equivalent to smoking 20 cigarettes per day for a year.

### Variable importance and interactions

We used Kernel Shapely Additive Explanations (SHAP) to disentangle the contribution of different variables to predictions, including interactions between variables.<sup>25</sup> Kernel SHAP is a feature attribution method designed to explain model predictions through the calculation of Shapely values, whose values represent the contribution made by individual predictors to the overall prediction.<sup>25</sup>

Shapely values are calculated by iteratively passing each predictor through a model and attributing changes in the predicted outcomes for an individual in its absence to the predictor. As an example, for an individual with an age of 55, smoking duration of 30 years and pack-years of 60, the change in prediction made if the model only used smoking duration and pack-years can be attributed to age. These attributions are subsequently averaged across the dataset to get the final Shapely values for each predictor.<sup>26</sup> With SHAP, the result is a linear model  $\phi_0 + \sum \phi_i x_i$ , <sup>25</sup> where  $\phi_0$  is an intercept corresponding to the average predicted risk in the dataset being explained, along with the SHAP values  $\phi_i$  for each of the predictors  $x_i$  (i.e., age, smoking duration, and pack-years).

Supplementary Results

	Lung cancer n=3,449	No lung cancer n=213,265	Lung cancer death n=2,137	No lung cancer death n=214,577	All participants n=216,714
Age (n, %)				·	
<50	123 (3.57)	43,047 (20.18)	75 (3.51)	43,095 (20.08)	43,170 (19.92)
50-54	243 (7.05)	29,834 (13.99)	152 (7.11)	29,925 (13.95)	30,077 (13.88)
55-59	556 (16.12)	38,983 (18.28)	347 (16.24)	39,192 (18.26)	39,539 (18.24)
60-64	1,180 (34.21)	56,115 (26.31)	712 (33.32)	56,583 (26.37)	57,295 (26.44)
65-69	1,316 (38.16)	44,204 (20.73)	834 (39.03)	44,686 (20.83)	45,520 (21.0)
≥70	31 (0.9)	1,082 (0.51)	17 (0.8)	1,096 (0.51)	1,113 (0.51)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Sex - Female (n, %)	1,574 (45.64)	102,124 (47.89)	936 (43.8)	102,762 (47.89)	103,698 (47.85)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity - White (n, %)	3,368 (98.02)	204,887 (96.44)	2,097 (98.36)	206,158 (96.45)	208,255 (96.47)
Missing	13 (0.38)	817 (0.38)	5 (0.23)	825 (0.38)	830 (0.38)
Highest qualification (n, %)					
Degree	478 (14.3)	59,227 (28.29)	276 (13.29)	59,429 (28.22)	59,705 (28.07)
Some college	310 (9.28)	16,191 (7.73)	200 (9.63)	16,301 (7.74)	16,501 (7.76)
Post-secondary school	450 (13.46)	33,138 (15.83)	275 (13.24)	33,313 (15.82)	33,588 (15.79)
Secondary school	725 (21.69)	56,921 (27.19)	437 (21.04)	57,209 (27.17)	57,646 (27.11)
None of the above	1,379 (41.26)	43,852 (20.95)	889 (42.8)	44,342 (21.06)	45,231 (21.27)
Missing	107 (3.1)	3936 (1.85)	60 (2.81)	3983 (1.86)	4043 (1.87)
In paid employment/self-employed (n, %)	1,071 (31.16)	115,762 (54.47)	629 (29.49)	116,204 (54.35)	116,833 (54.1)
Missing	12 (0.35)	755 (0.35)	4 (0.19)	763 (0.36)	767 (0.35)
Body mass index					
<18.5	46 (1.35)	1,038 (0.49)	29 (1.37)	1,055 (0.49)	1,084 (0.5)
18.5-24	1,046 (30.65)	61,669 (29.08)	652 (30.78)	62,063 (29.09)	62,715 (29.1)
25-29	1,437 (42.1)	92,835 (43.77)	904 (42.68)	93,368 (43.76)	94,272 (43.75)
30-34	665 (19.48)	40,804 (19.24)	403 (19.03)	41,066 (19.25)	41,469 (19.24)
≥35	219 (6.42)	15,735 (7.42)	130 (6.14)	15,824 (7.42)	15,954 (7.4)
Missing	36 (1.04)	1,184 (0.56)	19 (0.89)	1,201 (0.56)	1,220 (0.56)
Household income (GBP $\pounds$ )					
<18,000	1,318 (47.6)	47,749 (26.13)	864 (50.2)	48,203 (26.23)	49,067 (26.45)
18,000-30,999	790 (28.53)	48,233 (26.39)	492 (28.59)	48,531 (26.4)	49,023 (26.42)
31,000-51,999	404 (14.59)	45,716 (25.01)	230 (13.36)	45,890 (24.97)	46,120 (24.86)
52,000-100,000	208 (7.51)	32,812 (17.95)	110 (6.39)	32,910 (17.9)	33,020 (17.8)
>100,000	49 (1.77)	8,247 (4.51)	25 (1.45)	8,271 (4.5)	8,296 (4.47)
Missing	680 (19.72)	30,508 (14.31)	416 (19.47)	30,772 (14.34)	31,188 (14.39)
					Continued
Smoking status					
Former	1,817 (52.68)	162,897 (76.38)	1,073 (50.21)	163,641 (76.26)	164,714 (76.01)
Current	1,632 (47.32)	50,368 (23.62)	1,064 (49.79)	50,936 (23.74)	52,000 (23.99)

# eTable 5: Descriptive characteristics of UK Biobank ever-smokers by outcome

	Lung cancer n=3,449	No lung cancer n=213,265	Lung cancer death n=2,137	No lung cancer death n=214,577	All participants n=216,714
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Age started smoking					
<16	1,223 (38.34)	47,210 (30.34)	792 (39.94)	47,641 (30.38)	48,433 (30.5)
16-20	1,658 (51.97)	87,974 (56.54)	997 (50.28)	88,635 (56.53)	89,632 (56.45)
>20	309 (9.69)	20,403 (13.11)	194 (9.78)	20,518 (13.09)	20,712 (13.04)
Missing	259 (7.51)	57,678 (27.05)	154 (7.21)	57,783 (26.93)	57,937 (26.73)
Years smoked					
<10	54 (1.7)	16,910 (10.9)	31 (1.57)	16,933 (10.83)	16,964 (10.71)
10-19	176 (5.53)	36,641 (23.62)	105 (5.31)	36,712 (23.48)	36,817 (23.25)
20-29	386 (12.14)	38,039 (24.52)	201 (10.16)	38,224 (24.45)	38,425 (24.27)
30-39	787 (24.75)	35,610 (22.95)	480 (24.27)	35,917 (22.97)	36,397 (22.99)
≥40	1,777 (55.88)	27,954 (18.02)	1,161 (58.7)	28,570 (18.27)	29,731 (18.78)
Missing	269 (7.8)	58,111 (27.25)	159 (7.44)	58,221 (27.13)	58,380 (26.94)
Cigarettes per day (median, IQR)					
1-10	547 (18.26)	41,797 (28.4)	338 (18.14)	42,006 (28.32)	42,344 (28.2)
11-20	1,575 (52.57)	76,880 (52.24)	977 (52.44)	77,478 (52.24)	78,455 (52.24)
21-30	545 (18.19)	18,653 (12.67)	336 (18.04)	18,862 (12.72)	19,198 (12.78)
31-40	240 (8.01)	6,837 (4.65)	153 (8.21)	6,924 (4.67)	7,077 (4.71)
>40	89 (2.97)	3,013 (2.05)	59 (3.17)	3,043 (2.05)	3,102 (2.07)
Missing	453 (13.13)	66,085 (30.99)	274 (12.82)	66,264 (30.88)	66,538 (30.7)
Pack-years of smoking (n, %)					
<10	155 (5.21)	35,067 (23.96)	91 (4.91)	35,131 (23.82)	35,222 (23.59)
10-19	371 (12.46)	39,543 (27.02)	218 (11.76)	39,696 (26.92)	39,914 (26.73)
20-29	538 (18.07)	28,933 (19.77)	321 (17.31)	29,150 (19.77)	29,471 (19.74)
30-39	595 (19.99)	20,001 (13.67)	362 (19.53)	20,234 (13.72)	20,596 (13.79)
≥40	1,318 (44.27)	22,807 (15.58)	862 (46.49)	23,263 (15.77)	24,125 (16.16)
Missing	472 (13.69)	66,914 (31.38)	283 (13.24)	67,103 (31.27)	67,386 (31.09)
Personal history of cancer (n, %)	515 (14.93)	18,871 (8.85)	291 (13.62)	19,095 (8.9)	19,386 (8.95)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
COPD / Emphysema / Bronchitis (n, %)	409 (11.9)	6,207 (2.92)	248 (11.64)	6,368 (2.97)	6,616 (3.06)
Missing	13 (0.38)	441 (0.21)	7 (0.33)	447 (0.21)	454 (0.21)
Family history of lung cancer (n, %)	797 (23.72)	27,968 (13.36)	473 (22.78)	28,292 (13.43)	28,765 (13.52)
Missing	89 (2.58)	3,855 (1,81)	61 (2.85)	3 883 (1 81)	3 944 (1 82)

# eTable 5: Descriptive characteristics of UK Biobank ever-smokers by outcome

	Lung cancer n=960	No lung cancer n=25,656	Lung cancer death n=545	No lung cancer death n=26,071	All participants n=26,616
Age (n, %)					
55-59	247 (25.73)	11,137 (43.41)	139 (25.5)	11,245 (43.13)	11,384 (42.77)
60-64	299 (31.15)	7,871 (30.68)	165 (30.28)	8,005 (30.7)	8,170 (30.7)
65-69	250 (26.04)	4,491 (17.5)	141 (25.87)	4,600 (17.64)	4,741 (17.81)
70-74	164 (17.08)	2,157 (8.41)	100 (18.35)	2,221 (8.52)	2,321 (8.72)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Sex – Female (n, %)	390 (40.62)	10,529 (41.04)	212 (38.9)	10,707 (41.07)	10,919 (41.02)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity – White (n, %)	871 (91.2)	23,294 (91.51)	492 (91.28)	23,673 (91.5)	24,165 (91.5)
Missing	5 (0.52)	201 (0.78)	6 (1.1)	200 (0.77)	206 (0.77)
Qualifications (n, %)					
Degree	214 (22.43)	7,999 (31.36)	116 (21.56)	8,097 (31.23)	8,213 (31.03)
Some college	209 (21.91)	5,863 (22.98)	121 (22.49)	5,951 (22.95)	6,072 (22.94)
Post-secondary school	430 (45.07)	9,670 (37.91)	247 (45.91)	9,853 (38.0)	10,100 (38.17)
Secondary school	67 (7.02)	1,144 (4.48)	40 (7.43)	1,171 (4.52)	1,211 (4.58)
None of the above	34 (3.56)	834 (3.27)	14 (2.6)	854 (3.29)	868 (3.28)
Missing	6 (0.62)	146 (0.57)	7 (1.28)	145 (0.56)	152 (0.57)
Body mass index (n, %)					
<18.5	13 (1.37)	227 (0.89)	10 (1.86)	230 (0.89)	240 (0.91)
18.5-24	339 (35.61)	6,963 (27.35)	193 (35.87)	7,109 (27.48)	7,302 (27.65)
25-29	400 (42.02)	11,042 (43.38)	221 (41.08)	11,221 (43.37)	11,442 (43.33)
30-34	144 (15.13)	5,075 (19.94)	88 (16.36)	5,131 (19.83)	5,219 (19.76)
≥35	56 (5.88)	2,149 (8.44)	26 (4.83)	2,179 (8.42)	2,205 (8.35)
Missing	8 (0.83)	200 (0.78)	7 (1.28)	201 (0.77)	208 (0.78)
Smoking status (n, %)					
Former	362 (37.71)	13,402 (52.24)	189 (34.68)	13,575 (52.07)	13,764 (51.71)
Current	598 (62.29)	12,254 (47.76)	356 (65.32)	12,496 (47.93)	12,852 (48.29)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Age started smoking (n, %)					
<16	408 (42.5)	9,524 (37.12)	229 (42.02)	9,703 (37.22)	9,932 (37.32)
16-20	471 (49.06)	13,304 (51.86)	268 (49.17)	13,507 (51.81)	13,775 (51.75)
>20	81 (8.44)	2,828 (11.02)	48 (8.81)	2,861 (10.97)	2,909 (10.93)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Years smoked (n, %)					
<10	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
10-19	1 (0.1)	66 (0.26)	0 (0.0)	67 (0.26)	67 (0.25)
20-29	14 (1.46)	1,749 (6.82)	10 (1.83)	1,753 (6.72)	1,763 (6.62)
30-39	196 (20.42)	10,296 (40.13)	110 (20.18)	10,382 (39.82)	10,492 (39.42)
≥40	749 (78.02)	13,545 (52.79)	425 (77.98)	13,869 (53.2)	14,294 (53.7)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
					Continued

# eTable 6: Descriptive characteristics of NLST control ever-smokers by outcome

	Lung cancer n=960	No lung cancer n=25,656	Lung cancer death n=545	No lung cancer death n=26,071	All participants n=26,616
Cigarettes per day (n, %)					
<10	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
10-19	42 (4.38)	1,335 (5.2)	17 (3.12)	1,360 (5.22)	1,377 (5.17)
20-29	436 (45.42)	12,321 (48.02)	243 (44.59)	12,514 (48.0)	12,757 (47.93)
30-39	221 (23.02)	5,995 (23.37)	129 (23.67)	6,087 (23.35)	6,216 (23.35)
≥40	261 (27.19)	6,005 (23.41)	156 (28.62)	6,110 (23.44)	6,266 (23.54)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pack-years of smoking (n, %)					
<10	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
10-19	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
20-29	0 (0.0)	4 (0.02)	0 (0.0)	4 (0.02)	4 (0.02)
30-39	112 (11.67)	6,753 (26.32)	59 (10.83)	6,806 (26.11)	6,865 (25.79)
≥40	848 (88.33)	18,899 (73.66)	486 (89.17)	19,261 (73.88)	19,747 (74.19)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Personal history of cancer (n, %)	59 (6.15)	1,138 (4.44)	29 (5.32)	1,168 (4.48)	1,197 (4.5)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
COPD/Emphysema/Chronic bronchitis (n, %)	267 (27.81)	4,350 (16.96)	131 (24.04)	4,486 (17.21)	4,617 (17.35)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Family history of lung cancer (n, %)	256 (26.67)	5,478 (21.35)	142 (26.06)	5,592 (21.45)	5,734 (21.54)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

# eTable 6: Descriptive characteristics of NLST control ever-smokers by outcome

	Lung cancer n=1,734	No lung cancer n=38,859	Lung cancer death n=1,782	No lung cancer death n=38,811	All participants n=40,593
Age (n, %)	,				
55-59	357 (20.6)	13,608 (35.03)	382 (21.44)	13,583 (35.01)	13,965 (34.41)
60-64	514 (29.66)	12,109 (31.17)	541 (30.36)	12,082 (31.14)	12,623 (31.1)
65-69	548 (31.62)	8,569 (22.06)	560 (31.43)	8,557 (22.05)	9,117 (22.46)
≥70	314 (18.12)	4,565 (11.75)	299 (16.78)	4,580 (11.8)	4,879 (12.02)
Missing	1 (0.06)	8 (0.02)	0 (0.0)	9 (0.02)	9 (0.02)
Sex - Female (n, %)	641 (36.97)	16,251 (41.82)	630 (35.35)	16,262 (41.9)	16,892 (41.61)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity - White (n, %)	1,520 (87.66)	34,298 (88.31)	1,535 (86.19)	34,283 (88.38)	35,818 (88.29)
Missing	0 (0.0)	23 (0.06)	1 (0.06)	22 (0.06)	23 (0.06)
Highest qualification (n, %)					
Degree	402 (23.2)	12,747 (32.85)	424 (23.79)	12,725 (32.84)	13,149 (32.44)
Some college	400 (23.08)	9,034 (23.28)	423 (23.74)	9,011 (23.25)	9,434 (23.27)
Post-secondary school	679 (39.18)	13,724 (35.37)	685 (38.44)	13,718 (35.4)	14,403 (35.53)
Secondary school	225 (12.98)	2,858 (7.37)	216 (12.12)	2,867 (7.4)	3,083 (7.61)
None of the above	27 (1.56)	437 (1.13)	34 (1.91)	430 (1.11)	464 (1.14)
Missing	1 (0.06)	59 (0.15)	0 (0.0)	60 (0.15)	60 (0.15)
Body mass index					
<18.5	18 (1.05)	292 (0.76)	22 (1.25)	288 (0.75)	310 (0.77)
18.5-24	660 (38.57)	12,083 (31.48)	656 (37.19)	12,087 (31.53)	12,743 (31.78)
25-29	708 (41.38)	16,572 (43.18)	739 (41.89)	16,541 (43.15)	17,280 (43.1)
30-34	263 (15.37)	6,772 (17.64)	269 (15.25)	6,766 (17.65)	7,035 (17.55)
≥35	62 (3.62)	2,664 (6.94)	78 (4.42)	2,648 (6.91)	2,726 (6.8)
Missing	23 (1.33)	476 (1.22)	18 (1.01)	481 (1.24)	499 (1.23)
Smoking status					
Current	772 (44.52)	7,301 (18.79)	818 (45.9)	7,255 (18.69)	8,073 (19.89)
Previous	962 (55.48)	31,558 (81.21)	964 (54.1)	31,556 (81.31)	32,520 (80.11)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Age started smoking					
<16	468 (27.29)	7,357 (19.04)	450 (25.57)	7,375 (19.11)	7,825 (19.39)
16-20	978 (57.03)	23,374 (60.49)	1,029 (58.47)	23,323 (60.43)	24,352 (60.35)
>20	269 (15.69)	7,907 (20.46)	281 (15.97)	7,895 (20.46)	8,176 (20.26)
Missing	19 (1.1)	221 (0.57)	22 (1.23)	218 (0.56)	240 (0.59)
Years smoked					
<10	23 (1.35)	4,688 (12.3)	17 (0.97)	4,694 (12.33)	4,711 (11.83)
1-19	98 (5.75)	7,788 (20.43)	98 (5.61)	7,788 (20.46)	7,886 (19.81)
20-29	184 (10.8)	8,064 (21.16)	206 (11.78)	8,042 (21.12)	8,248 (20.71)
30-39	416 (24.41)	9,068 (23.79)	418 (23.91)	9,066 (23.81)	9,484 (23.82)
≥40	983 (57.69)	8,505 (22.32)	1,009 (57.72)	8,479 (22.27)	9,488 (23.83)
Missing	30 (1.73)	746 (1.92)	34 (1.91)	742 (1.91)	776 (1.91)

# eTable 7: Descriptive characteristics of PLCO radiography arm ever-smokers by outcome

Cigarettes per day (n, %)

	Lung cancer n=1,734	No lung cancer n=38,859	Lung cancer death n=1,782	No lung cancer death n=38,811	All participants n=40,593
1-10	197 (11.41)	10,237 (26.39)	205 (11.54)	10,229 (26.41)	10,434 (25.76)
11-20	611 (35.38)	14,331 (36.95)	636 (35.79)	14,306 (36.93)	14,942 (36.88)
21-30	446 (25.83)	7,503 (19.35)	479 (26.96)	7,470 (19.29)	7,949 (19.62)
31-40	297 (17.2)	4,097 (10.56)	279 (15.7)	4,115 (10.62)	4,394 (10.85)
>40	176 (10.19)	2,616 (6.75)	178 (10.02)	2,614 (6.75)	2,792 (6.89)
Missing	7 (0.4)	75 (0.19)	5 (0.28)	77 (0.2)	82 (0.2)
Pack-years of smoking (n, %)					
<10	39 (2.3)	6,570 (17.26)	34 (1.95)	6,575 (17.3)	6,609 (16.63)
10-19	114 (6.71)	7,491 (19.69)	120 (6.88)	7,485 (19.69)	7,605 (19.13)
20-29	170 (10.01)	5,669 (14.9)	182 (10.44)	5,657 (14.88)	5,839 (14.69)
30-39	168 (9.89)	4,940 (12.98)	164 (9.4)	4,944 (13.01)	5,108 (12.85)
≥40	1,208 (71.1)	13,384 (35.17)	1,244 (71.33)	13,348 (35.12)	14,592 (36.71)
Missing	35 (2.02)	805 (2.07)	38 (2.13)	802 (2.07)	840 (2.07)
Personal history of cancer (n, %)	97 (5.59)	1,740 (4.48)	96 (5.39)	1,741 (4.49)	1,837 (4.53)
Missing	0 (0.0)	5 (0.01)	0 (0.0)	5 (0.01)	5 (0.01)
COPD / Emphysema / Bronchitis (n, %)	308 (17.76)	3,309 (8.52)	295 (16.55)	3,322 (8.56)	3,617 (8.91)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Family history of lung cancer (n, %)	292 (17.95)	4,274 (11.44)	297 (17.74)	4,269 (11.44)	4,566 (11.71)
Missing	107 (6.17)	1495 (3.85)	108 (6.06)	1494 (3.85)	1602 (3.95)

# eTable 7: Descriptive characteristics of PLCO radiography arm ever-smokers by outcome

	Lung cancer n=3,356	No lung cancer n=77,303	Lung cancer death n=3,534	No lung cancer death n=77,125	All participants n=80,659
Age (n, %)					
55-59	692 (20.63)	26,886 (34.79)	743 (21.02)	26,835 (34.8)	27,578 (34.2)
60-64	1,013 (30.19)	24,095 (31.18)	1,097 (31.04)	24,011 (31.14)	25,108 (31.14)
65-69	1,035 (30.85)	17,069 (22.09)	1,107 (31.32)	16,997 (22.04)	18,104 (22.45)
≥70	615 (18.33)	9,233 (11.95)	587 (16.61)	9,261 (12.01)	9,848 (12.21)
Missing	1 (0.03)	20 (0.03)	0 (0.0)	21 (0.03)	21 (0.03)
Sex - Female (n, %)	1,263 (37.63)	32,484 (42.02)	1,281 (36.25)	32,466 (42.1)	33,747 (41.84)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity - White (n, %)	2,978 (88.74)	68,252 (88.34)	3,085 (87.32)	68,145 (88.4)	71,230 (88.36)
Missing	0 (0.0)	43 (0.06)	1 (0.03)	42 (0.05)	43 (0.05)
Highest qualification (n, %)					
Degree	777 (23.19)	25,126 (32.59)	838 (23.75)	25,065 (32.58)	25,903 (32.2)
Some college	776 (23.16)	17,978 (23.32)	815 (23.09)	17,939 (23.32)	18,754 (23.31)
Post-secondary school	1,341 (40.02)	27,394 (35.53)	1,393 (39.47)	27,342 (35.54)	28,735 (35.72)
Secondary school	414 (12.35)	5,726 (7.43)	423 (11.99)	5,717 (7.43)	6,140 (7.63)
None of the above	43 (1.28)	877 (1.14)	60 (1.7)	860 (1.12)	920 (1.14)
Missing	5 (0.15)	202 (0.26)	5 (0.14)	202 (0.26)	207 (0.26)
Body mass index					
<18.5	44 (1.33)	562 (0.74)	50 (1.43)	556 (0.73)	606 (0.76)
18.5-24	1,258 (38.03)	24,084 (31.65)	1,286 (36.9)	24,056 (31.68)	25,342 (31.91)
25-29	1,387 (41.93)	33,013 (43.38)	1,471 (42.21)	32,929 (43.37)	34,400 (43.32)
30-34	482 (14.57)	13,249 (17.41)	510 (14.63)	13,221 (17.41)	13,731 (17.29)
≥35	137 (4.14)	5,194 (6.83)	168 (4.82)	5,163 (6.8)	5,331 (6.71)
Missing	48 (1.43)	1201 (1.55)	49 (1.39)	1200 (1.56)	1249 (1.55)
Smoking status					
Former	1,840 (54.83)	62,769 (81.2)	1,910 (54.05)	62,699 (81.3)	64,609 (80.1)
Current	1,516 (45.17)	14,534 (18.8)	1,624 (45.95)	14,426 (18.7)	16,050 (19.9)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Age started smoking					
<16	865 (26.07)	14,583 (18.98)	880 (25.21)	14,568 (19.0)	15,448 (19.27)
16-20	1,936 (58.35)	46,507 (60.52)	2,058 (58.95)	46,385 (60.5)	48,443 (60.43)
>20	517 (15.58)	15,755 (20.5)	553 (15.84)	15,719 (20.5)	16,272 (20.3)
Missing	38 (1.13)	458 (0.59)	43 (1.22)	453 (0.59)	496 (0.61)
Years smoked					
<10	51 (1.55)	9,171 (12.12)	48 (1.38)	9,174 (12.15)	9,222 (11.67)
10-19	179 (5.43)	15,358 (20.29)	196 (5.65)	15,341 (20.31)	15,537 (19.67)
20-29	344 (10.44)	16,048 (21.2)	386 (11.13)	16,006 (21.19)	16,392 (20.75)
30-39	803 (24.37)	18,008 (23.79)	842 (24.28)	17,969 (23.79)	18,811 (23.81)
≥40	1,918 (58.21)	17,110 (22.6)	1,996 (57.55)	17,032 (22.55)	19,028 (24.09)
Missing	61 (1.82)	1608 (2.08)	66 (1.87)	1603 (2.08)	1669 (2.07)
					Continued

# eTable 8: Descriptive characteristics of all PLCO ever-smokers by outcome

				NI 1	
	Lung cancer n=3,356	No lung cancer n=77,303	Lung cancer death n=3,534	No lung cancer death n=77,125	All participants n=80,659
Cigarettes per day (n, %)					
1-10	379 (11.33)	20,249 (26.26)	404 (11.46)	20,224 (26.29)	20,628 (25.64)
11-20	1,155 (34.54)	28,180 (36.54)	1,247 (35.37)	28,088 (36.51)	29,335 (36.46)
21-30	894 (26.73)	15,131 (19.62)	953 (27.03)	15,072 (19.59)	16,025 (19.92)
31-40	555 (16.6)	8,285 (10.74)	558 (15.83)	8,282 (10.76)	8,840 (10.99)
>40	361 (10.8)	5,274 (6.84)	364 (10.32)	5,271 (6.85)	5,635 (7.0)
Missing	12 (0.36)	184 (0.24)	8 (0.23)	188 (0.24)	196 (0.24)
Pack-years of smoking (n, %)					
<10	88 (2.68)	12,874 (17.04)	86 (2.48)	12,876 (17.08)	12,962 (16.44)
10-19	196 (5.97)	14,648 (19.39)	219 (6.33)	14,625 (19.4)	14,844 (18.83)
20-29	320 (9.74)	11,382 (15.06)	356 (10.29)	11,346 (15.05)	11,702 (14.84)
30-39	328 (9.98)	9,850 (13.04)	341 (9.85)	9,837 (13.05)	10,178 (12.91)
≥40	2,353 (71.63)	26,805 (35.48)	2,459 (71.05)	26,699 (35.42)	29,158 (36.98)
Missing	71 (2.12)	1744 (2.26)	73 (2.07)	1742 (2.26)	1815 (2.25)
Personal history of cancer (n, %)	216 (6.44)	3,480 (4.5)	220 (6.23)	3,476 (4.51)	3,696 (4.58)
Missing	0 (0.0)	17 (0.02)	0 (0.0)	17 (0.02)	17 (0.02)
COPD / Emphysema / Bronchitis (n, %)	607 (18.09)	6,615 (8.56)	584 (16.53)	6,638 (8.61)	7,222 (8.95)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Family history of lung cancer (n, %)	562 (17.73)	8,479 (11.39)	573 (17.2)	8,468 (11.4)	9,041 (11.65)
Missing	187 (5.57)	2891 (3.74)	202 (5.72)	2876 (3.73)	3078 (3.82)

# eTable 8: Descriptive characteristics of all PLCO ever-smokers by outcome

еΤ	able	9:	Outcomes	by	dataset
----	------	----	----------	----	---------

	UK Bi	obank	NLST control arm PLCO ever-smokers (intervention arm)		PLCO ever-smokers (all)			
Years	Lung cancers (n)	Deaths from lung cancer (n)	Lung cancers (n)	Deaths from lung cancer (n)	Lung cancers (n)	Deaths from lung cancer (n)	Lung cancers (n)	Deaths from lung cancer (n)
1	202	55	185	36	169	32	261	55
2	439	194	314	105	281	105	489	195
3	712	356	442	186	412	188	747	358
4	1010	548	572	276	543	271	993	534
5	1335	737	719	365	643	351	1231	727
6	1653	956	885	481	754	445	1464	914
7	2060	1189	957	545	915	538	1744	1106
8	2456	1463	959	-	1046	655	2019	1329
9	2790	1722	-	-	1184	777	2303	1566
10	3112	1930	-	-	1330	881	2573	1770

UK Biobank and the US National Lung Screening Trial were model development datasets. External validation occurred amongst ever-smokers in the PLCO intervention arm and amongst all ever-smokers in the PLCO.

	Predictors	AUC – UK Biobank	AUC – PLCO radiography arm
UCL-D	3	0.826 (0.815-0.838)	0.803 (0.783-0.824)
Cox model (no interactions)	3	0.817 (0.809-0.825)	0.782 (0.772-0.793)
Cox model with interactions	3	0.819 (0.811-0.827)	0.785 (0.775-0.795)
LCDRAT-constrained	6	0.821 (0.807-0.833)	0.801 (0.782-0.820)
LCRAT-constrained	6	0.806 (0.796-0.819)	0.788 (0.773-0.803)
PLCOm2012-constrained	5	0.786 (0.772-0.799)	0.778 (0.766-0.797)

**eTable 10:** Discrimination of UCL-D, Cox models, and the constrained LCDRAT, LCRAT, and PLCOm2012 models

UCL-D, the two Cox models, and LCDRAT-constrained predict 5-year risk of lung cancer death; LCRAT-constrained and PLCOm2012 constrained 5-year risk of lung cancer occurrence. Cox models were modelled with restricted cubic splines, with and without mutual interactions between age, smoking duration, and pack-years. The LCDRAT and LCRAT-constrained models use age, sex, quit-years, smoking duration, cigarettes per day, and pack-years. PLCOm2012-constrained uses age, smoking status, smoking duration, cigarettes per day, and quit-years. Both the LCRAT/LCDRAT and PLCOm2012 models were developed in the control arm of the PLCO trial. The relatively shallow drop-off in discriminatory performance between the various constrained models and their full versions show the relative importance of few smoking parameters and validates our findings that few smoking variables drive all lung cancer models in ever-smokers. The improvement seen by UCL-D over Cox models using the same data and variables reflects the statistical advantages of ensemble machine learning approaches.

# eTable 11: Brier scores in UK Biobank and PLCO radiography arm

	Risk of death fr	om lung cancer		Risk of develop	oing lung cancer	
	UCL-D	LCDRAT	UCL-I	LCRAT	PLCOm2012*	LLPv2
			UK Biobank			
Overall	0.0034 (0.0031-0.0036)	0.0034 (0.0031-0.0036)	0.006 (0.0058-0.0064)	0.006 (0.0057-0.0063)	0.006 (0.0057-0.0063)	0.0062 (0.0059-0.0065)
Age category						
40-49	0.0005 (0.0002-0.0007)	0.0005 (0.0002-0.0007)	0.0009 (0.0006-0.0012)	0.0009 (0.0006-0.0013)	0.0009 (0.0006-0.0013)	0.0009 (0.0006-0.0013)
50-59	0.0025 (0.0022-0.0029)	0.0025 (0.0021-0.0028)	0.0043 (0.0038-0.0047)	0.0042 (0.0038-0.0048)	0.0042 (0.0038-0.0048)	0.0042 (0.0038-0.0049)
60-72	0.0052 (0.0047-0.0056)	0.0051 (0.0048-0.0056)	0.0094 (0.0088-0.0100)	0.0093 (0.0090-0.0099)	0.0094 (0.0090-0.0099)	0.0097 (0.0093-0.0102)
Sex						
Female	0.0029 (0.0026-0.0031)	0.0028 (0.0025-0.0032)	0.0056 (0.0051-0.0060)	0.0055 (0.0050-0.0059)	0.0055 (0.0050-0.0059)	0.0056 (0.0050-0.0059)
Male	0.0039 (0.0035-0.0042)	0.0038 (0.0035-0.0042)	0.0065 (0.0061-0.0070)	0.0065 (0.0061-0.0069)	0.0065 (0.0061-0.0069)	0.0068 (0.0063-0.0072)
Smoking status						
Former	0.0023 (0.0020-0.0025)	0.0022 (0.0020-0.0025)	0.0043 (0.0041-0.0046)	0.0043 (0.0040-0.0046)	0.0043 (0.0040-0.0046)	0.0044 (0.0042-0.0047)
Current	0.0069 (0.0061-0.0076)	0.0069 (0.0062-0.0075)	0.0115 (0.0107-0.0124)	0.0115 (0.0107-0.0123)	0.0115 (0.0107-0.0123)	0.0117 (0.0109-0.0125)
Ethnicity						
Other	0.0017 (0.0006-0.0023)	0.0015 (0.0008-0.0023)	0.0031 (0.0019-0.0042)	0.0029 (0.0020-0.0041)	0.0029 (0.0020-0.0040)	0.0030 (0.0022-0.0042)
White	0.0034 (0.0032-0.0037)	0.0034 (0.0032-0.0037)	0.0062 (0.0059-0.0065)	0.0061 (0.0058-0.0064)	0.0062 (0.0059-0.0065)	0.0063 (0.0060-0.0066)
Household income						
<18,000	0.0059 (0.0052-0.0064)	0.0059 (0.0052-0.0065)	0.0104 (0.0096-0.0112)	0.0103 (0.0095-0.0112)	0.0103 (0.0095-0.0113)	0.0105 (0.0097-0.0115)
18,000 to 30,999	0.0038 (0.0033-0.0042)	0.0037 (0.0033-0.0042)	0.0068 (0.0062-0.0074)	0.0068 (0.0061-0.0075)	0.0068 (0.0062-0.0075)	0.0070 (0.0064-0.0077)
31,000 to 51,999	0.0019 (0.0015-0.0021)	0.0018 (0.0015-0.0022)	0.0034 (0.0029-0.0039)	0.0033 (0.0029-0.0039)	0.0033 (0.0029-0.0039)	0.0035 (0.0030-0.0040)
52,000 to 100,000	0.0013 (0.0009-0.0016)	0.0013 (0.0010-0.0017)	0.0024 (0.0019-0.0029)	0.0024 (0.0019-0.0029)	0.0024 (0.0019-0.0029)	0.0024 (0.0020-0.0030)
>100,000	0.0012 (0.0003-0.0017)	0.0011 (0.0006-0.0018)	0.0021 (0.0011-0.0029)	0.0020 (0.0013-0.0031)	0.0020 (0.0013-0.0031)	0.0021 (0.0013-0.0032)
			PLCO radiography arr	n		
Overall	0.0084 (0.0075-0.0093)	0.0084 (0.0075-0.0093)	0.0153 (0.0142-0.0164)	0.0152 (0.0143-0.0164)	0.0153 (0.0143-0.0164)	0.0153 (0.0143-0.0165)

Age category						
55-59	0.0046 (0.0037-0.0057)	0.0046 (0.0036-0.0057)	0.0090 (0.0077-0.0105)	0.0090 (0.0077-0.0105)	0.0090 (0.0077-0.0105)	0.0091 (0.0078-0.0106)
60-64	0.0068 (0.0059-0.0081)	0.0069 (0.0059-0.0082)	0.0127 (0.0110-0.0147)	0.0128 (0.0111-0.0147)	0.0128 (0.0111-0.0147)	0.0128 (0.0110-0.0148)
65-69	0.0122 (0.0100-0.0146)	0.0122 (0.0100-0.0145)	0.0224 (0.0198-0.0257)	0.0223 (0.0197-0.0254)	0.0222 (0.0197-0.0253)	0.0225 (0.0199-0.0259)
70-74	0.0160 (0.0129-0.0193)	0.0161 (0.0129-0.0193)	0.0261 (0.0219-0.0298)	0.0263 (0.0221-0.0299)	0.0265 (0.0226-0.0301)	0.0263 (0.0220-0.0300)
Sex						
Female	0.0071 (0.0058-0.0083)	0.0072 (0.0059-0.0084)	0.0138 (0.0125-0.0155)	0.0138 (0.0125-0.0155)	0.0139 (0.0125-0.0155)	0.0139 (0.0125-0.0156)
Male	0.0093 (0.0082-0.0107)	0.0093 (0.0082-0.0107)	0.0163 (0.0150-0.0180)	0.0162 (0.0149-0.0180)	0.0163 (0.0150-0.0180)	0.0163 (0.0151-0.0182)
Smoking status						
Former	0.0058 (0.0050-0.0066)	0.0059 (0.0050-0.0066)	0.0108 (0.0098-0.0118)	0.0108 (0.0098-0.0119)	0.0109 (0.0099-0.0119)	0.0109 (0.0099-0.0119)
Current	0.0187 (0.0160-0.0213)	0.0187 (0.0160-0.0214)	0.0329 (0.0300-0.0368)	0.0329 (0.0299-0.0366)	0.0330 (0.0300-0.0368)	0.0331 (0.0301-0.0371)
Qualifications						
Degree	0.0060 (0.0047-0.0072)	0.0060 (0.0047-0.0071)	0.0109 (0.0092-0.0126)	0.0109 (0.0091-0.0126)	0.0109 (0.0091-0.0125)	0.0110 (0.0092-0.0127)
Some college	0.0076 (0.0061-0.0095)	0.0076 (0.0061-0.0095)	0.0144 (0.0122-0.0165)	0.0144 (0.0122-0.0165)	0.0144 (0.0122-0.0165)	0.0145 (0.0123-0.0166)
Post-secondary	0.0091 (0.0077-0.0105)	0.0091 (0.0077-0.0105)	0.0166 (0.0148-0.0187)	0.0165 (0.0147-0.0187)	0.0166 (0.0148-0.0187)	0.0167 (0.0148-0.0189)
Secondary school	0.0157 (0.0119-0.0200)	0.0158 (0.0121-0.0201)	0.0273 (0.0222-0.0324)	0.0275 (0.0225-0.0325)	0.0276 (0.0227-0.0324)	0.0275 (0.0222-0.0326)
None of above	0.0210 (0.0102-0.0391)	0.0210 (0.0103-0.0387)	0.0315 (0.0146-0.0492)	0.0320 (0.0153-0.0496)	0.0322 (0.0158-0.0494)	0.0314 (0.0144-0.0490)
Ethnicity						
Asian	0.0069 (0.0031-0.0109)	0.0070 (0.0030-0.0110)	0.0111 (0.0056-0.0172)	0.0111 (0.0056-0.0174)	0.0112 (0.0057-0.0174)	0.0112 (0.0057-0.0173)
Black	0.0159 (0.0109-0.0209)	0.0158 (0.0109-0.0205)	0.0258 (0.0196-0.0316)	0.0256 (0.0197-0.0313)	0.0255 (0.0197-0.0309)	0.0257 (0.0196-0.0316)
Other	0.0106 (0.0058-0.0166)	0.0105 (0.0057-0.0165)	0.0146 (0.0091-0.0206)	0.0146 (0.0090-0.0205)	0.0150 (0.0095-0.0209)	0.0145 (0.0089-0.0202)
White	0.0079 (0.0070-0.0088)	0.0079 (0.0070-0.0089)	0.0148 (0.0136-0.0159)	0.0147 (0.0135-0.0158)	0.0148 (0.0136-0.0158)	0.0149 (0.0137-0.0160)

\* The PLCOm2012 score predicts 6-year risk of developing lung cancer, whilst all other scores predict risk at 5-years. The Brier score varies by prevalence, so results presented here are for PLCOm2012 against 5-year outcomes to allow for direct comparison. Lower Brier scores indicate better model performance.

	Risk threshold (%)	Sensitivity	Specificity
Predicting 5-year risk of death from lung cancer			
UCL-D	0.68	0.855 (0.828-0.882)	0.574 (0.570-0.577)
USPSTF-2021	-	0.775 (0.746-0.809)	0.574 (0.570-0.578)
Predicting 5-year risk of developing lung cancer			
UCL-I	1.17	0.839 (0.820-0.861)	0.577 (0.574-0.580)
USPSTF-2021	-	0.777 (0.758-0.802)	0.576 (0.572-0.579)

### eTable 12: Model sensitivity and sensitivity at specified risk thresholds in the PLCO dataset

Risk thresholds set using a fixed population approach at a level that would screen an equivalent number as the USPSTF-2021 in the PLCO external validation dataset. The entire PLCO dataset was used for these analyses.



#### eFigure 9: Outcomes by eligibility for either UCL-D or UCL-I, but not both UCL models

Kaplan-Meier plots showing lung cancer deaths (a) and lung cancers (b) amongst the 1,314 participants in the PLCO trial who would be eligible for screening with UCL-D (assuming a cut-off of 0.68%) but not UCL-I (assuming a cut-off of 1.17%) [blue lines] and amongst the 1,253 individuals who would be eligible for screening with UCL-I but not UCL-D [orange lines]. Overall, 34,756 individuals in the PLCO trial would have been eligible for screening with UCL-D at a cut-off of 0.68% and 34,695 with a cut-off of 1.17%. There is a trend shown in (a) towards those who would have been eligible for UCL-D but not UCL-I having a lower survival beyond 10 years (i.e., more deaths from lung cancer), but the difference did not reach statistical significance.





Net benefit across a range of thresholds of models predicting 5-year risk of death from lung cancer (A) and developing lung cancer (B) compared against USPSTF-2021 screening eligibility criteria in the UK Biobank dataset. Risk model-based approaches had a higher net benefit than screening either all men or using the USPSTF-2021 criteria to determine screening eligibility. The PLCOm2012 was originally fitted to predict 6-year risk of lung cancer; to make comparison possible, here net benefit was calculated based on predicting 5-year risk of lung cancer. The performance of PLCOm2012 over a 5-year timeframe was equivalent to that of a 6-year timeframe in the UK Biobank with an AUC of 0.796 (0.782-0.811) and a Brier score of 0.006 (0.0057-0.0063). In this analysis, the difference in net benefit between two approaches to selecting for screening at a particular risk threshold would be the change in true positives at that threshold level who would be screened given a fixed number of false positives.<sup>27</sup>

### **Full Models**

We present analyses in the full (control and radiography arm together) of the PLCO dataset. Here we also include the 'full' models developed alongside UCL-D and UCL. Both models are machine learning ensembles that were developed on the combined UK Biobank-NLST dataset.

### UCLFull-D

UCLFull-D is an eight-variable model that predicts five-year risk of death from lung cancer with the following predictors:

- 1. Age,
- 2. Smoking duration (years),
- 3. Pack-years,
- Smoking intensity (number of cigarettes per day),
   Quit-years,
- 6. Body-mass index,
- 7. Chronic obstructive pulmonary disease (COPD), and
- 8. Family history of lung cancer.

UCLFull - D = (0.143 \* AdaBoost) + (0.714 \* Logistic Regression) + (0.143 \* LightGBM)

#### **UCLFull-I**

UCLFull-I is a six-variable model that predicts five-year risk of developing lung cancer using the following predictors:

- 1. Age,
- 2. Smoking duration (years),
- 3. Pack-years,
- 4. Body-mass index,
- 5. COPD, and
- 6. family history of lung cancer.

#### UCLFull-I=

(0.391 \* CatBoost) + (0.391 \* Logistic Regression) + (0.087 \* AdaBoost) + (0.130 \* LightGBM)

	Risk	of death from lung c	ancer	Risk of developing lung cancer					
	UCLFull-D	UCL-D	LCDRAT	UCLFull-I	UCL-I	LCRAT	PLCOm2012	LLP v2	LLP v3
PLCO overall	0.80 (0.78-0.81)	0.79 (0.78-0.81)	0.80 (0.79-0.82)	0.79 (0.78-0.8)	0.78 (0.77-0.79)	0.79 (0.78-0.8)	0.79 (0.78-0.8)	0.74 (0.73-0.76)	0.74 (0.73-0.76)
Age category									
55-59	0.82 (0.78-0.84)	0.8 (0.77-0.83)	0.82 (0.78-0.85)	0.81 (0.78-0.83)	0.79 (0.77-0.82)	0.81 (0.79-0.84)	0.8 (0.78-0.82)	0.74 (0.71-0.76)	0.74 (0.71-0.77)
60-64	0.79 (0.76-0.81)	0.79 (0.75-0.81)	0.79 (0.76-0.81)	0.78 (0.76-0.80)	0.77 (0.75-0.80)	0.78 (0.76-0.80)	0.78 (0.77-0.80)	0.74 (0.71-0.76)	0.72 (0.70-0.75)
65-69	0.77 (0.74-0.80)	0.76 (0.73-0.79)	0.78 (0.75-0.80)	0.77 (0.74-0.79)	0.76 (0.74-0.78)	0.78 (0.75-0.80)	0.78 (0.76-0.80)	0.72 (0.70-0.75)	0.73 (0.70-0.75)
70-74	0.73 (0.70-0.77)	0.73 (0.70-0.77)	0.74 (0.71-0.78)	0.73 (0.70-0.76)	0.73 (0.70-0.76)	0.73 (0.71-0.76)	0.74 (0.71-0.77)	0.69 (0.66-0.72)	0.68 (0.65-0.71)
Sex									
Female	0.81 (0.79-0.83)	0.80 (0.78-0.82)	0.81 (0.79-0.84)	0.80 (0.78-0.81)	0.78 (0.76-0.8)	0.80 (0.78-0.81)	0.80 (0.78-0.81)	0.74 (0.72-0.76)	0.74 (0.72-0.76)
Male	0.79 (0.77-0.81)	0.78 (0.76-0.8)	0.80 (0.78-0.82)	0.79 (0.77-0.80)	0.78 (0.77-0.8)	0.79 (0.78-0.81)	0.79 (0.78-0.81)	0.75 (0.73-0.76)	0.75 (0.73-0.76)
Smoking status									
Former	0.81 (0.78-0.83)	0.80 (0.78-0.82)	0.81 (0.79-0.83)	0.79 (0.77-0.81)	0.79 (0.77-0.80)	0.79 (0.78-0.81)	0.79 (0.78-0.81)	0.75 (0.73-0.77)	0.74 (0.73-0.76)
Current	0.69 (0.66-0.72)	0.67 (0.64-0.70)	0.70 (0.67-0.73)	0.69 (0.67-0.71)	0.67 (0.65-0.69)	0.70 (0.68-0.72)	0.69 (0.67-0.71)	0.64 (0.61-0.66)	0.65 (0.62-0.67)
Qualifications									
Degree	0.83 (0.80-0.86)	0.83 (0.80-0.86)	0.84 (0.81-0.87)	0.82 (0.79-0.84)	0.81 (0.78-0.83)	0.82 (0.8-0.84)	0.82 (0.8-0.84)	0.77 (0.74-0.79)	0.77 (0.74-0.79)
Some college	0.79 (0.76-0.82)	0.79 (0.75-0.82)	0.78 (0.75-0.81)	0.79 (0.77-0.82)	0.79 (0.77-0.81)	0.79 (0.76-0.81)	0.80 (0.77-0.82)	0.75 (0.73-0.78)	0.74 (0.72-0.77)
Post-secondary	0.79 (0.77-0.82)	0.78 (0.75-0.80)	0.79 (0.77-0.81)	0.78 (0.76-0.80)	0.77 (0.75-0.79)	0.78 (0.76-0.8)	0.77 (0.76-0.79)	0.73 (0.71-0.75)	0.73 (0.71-0.75)
Secondary school	0.72 (0.67-0.78)	0.71 (0.66-0.77)	0.74 (0.68-0.78)	0.72 (0.67-0.76)	0.72 (0.67-0.76)	0.74 (0.69-0.77)	0.74 (0.70-0.77)	0.68 (0.63-0.72)	0.68 (0.63-0.72)
None of above	0.68 (0.57-0.78)	0.66 (0.53-0.76)	0.70 (0.58-0.81)	0.67 (0.56-0.75)	0.66 (0.57-0.75)	0.67 (0.55-0.76)	0.68 (0.58-0.77)	0.61 (0.51-0.73)	0.62 (0.51-0.74)
Ethnicity									
Asian	0.85 (0.79-0.91)	0.86 (0.80-0.91)	0.83 (0.76-0.90)	0.74 (0.64-0.84)	0.74 (0.62-0.84)	0.74 (0.66-0.83)	0.75 (0.67-0.82)	0.71 (0.61-0.81)	0.70 (0.59-0.81)
Black	0.79 (0.73-0.85)	0.78 (0.72-0.84)	0.81 (0.75-0.86)	0.78 (0.72-0.83)	0.77 (0.72-0.82)	0.79 (0.74-0.83)	0.79 (0.75-0.83)	0.75 (0.71-0.80)	0.74 (0.70-0.79)
Other	0.81 (0.72-0.90)	0.78 (0.67-0.87)	0.83 (0.76-0.91)	0.80 (0.74-0.86)	0.78 (0.71-0.85)	0.81 (0.74-0.87)	0.78 (0.70-0.84)	0.73 (0.64-0.83)	0.73 (0.64-0.83)
White	0.80 (0.78-0.81)	0.79 (0.78-0.80)	0.80 (0.78-0.81)	0.79 (0.78-0.80)	0.78 (0.77-0.79)	0.79 (0.78-0.81)	0.80 (0.79-0.81)	0.74 (0.73-0.76)	0.74 (0.73-0.76)

# eTable 13: Discriminative accuracy (AUC) in the whole PLCO cohort

Note that the LCDRAT, LCRAT, and PLCOm2012 models were developed in the control arm of the PLCO cohort. The relative performance of the UCL models is therefore notable.

	Risk of death from lung cancer				Risk of developing lung cancer					
	UCLFull-D	UCL-D	LCDRAT	UCLFull-I	UCL-I	LCRAT	PLCOm2012*	LLP v2	LLP v3	
PLCO overall	0.0088	0.0089	0.0088	0.0147	0.0147	0.0147	0.0147	0.0148	0.0149	
	(0.0083-0.0094)	(0.0083-0.0094)	(0.0083-0.0094)	(0.014-0.0155)	(0.0141-0.0155)	(0.0141-0.0155)	(0.0141-0.0155)	(0.0142-0.0156)	(0.0143-0.0157)	
Age category										
55-59	0.0048	0.0048	0.0048	0.0087	0.0087	0.0086	0.0087	0.0088	0.0088	
	(0.0042-0.0056)	(0.0042-0.0056)	(0.0041-0.0055)	(0.0077-0.0099)	(0.0077-0.0099)	(0.0077-0.0098)	(0.0077-0.0098)	(0.0077-0.01)	(0.0078-0.01)	
60-64	0.0074	0.0074	0.0074	0.0128	0.0128	0.0128	0.0128	0.0128	0.0129	
	(0.0063-0.0082)	(0.0063-0.0082)	(0.0063-0.0082)	(0.0114-0.0139)	(0.0115-0.014)	(0.0115-0.014)	(0.0115-0.014)	(0.0115-0.014)	(0.0115-0.0141)	
65-69	0.0127	0.0127	0.0127	0.0207	0.0208	0.0207	0.0207	0.021	0.0212	
	(0.0113-0.0143)	(0.0113-0.0144)	(0.0113-0.0143)	(0.019-0.0225)	(0.0191-0.0225)	(0.019-0.0224)	(0.019-0.0224)	(0.0192-0.0228)	(0.0193-0.023)	
70-74	0.0166	0.0167	0.0166	0.0254	0.0255	0.0255	0.0258	0.0256	0.0258	
	(0.0146-0.0192)	(0.0146-0.0192)	(0.0146-0.0192)	(0.0225-0.0279)	(0.0225-0.028)	(0.0226-0.0281)	(0.0228-0.0283)	(0.0227-0.0281)	(0.0227-0.0284)	
Sex										
Female	0.0072	0.0072	0.0073	0.013	0.013	0.013	0.0131	0.0131	0.0131	
	(0.0065-0.0081)	(0.0065-0.0081)	(0.0065-0.0081)	(0.0119-0.0141)	(0.012-0.0141)	(0.0119-0.0141)	(0.012-0.0142)	(0.0121-0.0142)	(0.0121-0.0143)	
Male	0.0099	0.0099	0.0099	0.0159	0.0159	0.0159	0.0159	0.016	0.0161	
	(0.009-0.0109)	(0.009-0.0109)	(0.009-0.0109)	(0.0146-0.017)	(0.0146-0.017)	(0.0146-0.017)	(0.0146-0.017)	(0.0147-0.0171)	(0.0148-0.0173)	
Smoking status										
Former	0.0062	0.0062	0.0062	0.0104	0.0104	0.0104	0.0104	0.0104	0.0104	
	(0.0057-0.0068)	(0.0057-0.0068)	(0.0057-0.0068)	(0.0096-0.0111)	(0.0096-0.0111)	(0.0096-0.0111)	(0.0096-0.0111)	(0.0096-0.0111)	(0.0097-0.0111)	
Current	0.0193	0.0194	0.0194	0.0322	0.0324	0.0323	0.0324	0.0326	0.033	
	(0.0172-0.021)	(0.0173-0.0211)	(0.0173-0.021)	(0.0298-0.0344)	(0.03-0.0346)	(0.0298-0.0344)	(0.03-0.0346)	(0.0301-0.0349)	(0.0304-0.0354)	
Qualifications										
Degree	0.0059	0.0059	0.0059	0.0104	0.0104	0.0104	0.0104	0.0105	0.0105	
	(0.0051-0.0068)	(0.0051-0.0069)	(0.0051-0.0069)	(0.0094-0.0116)	(0.0094-0.0117)	(0.0094-0.0116)	(0.0094-0.0116)	(0.0095-0.0117)	(0.0095-0.0118)	
Some college	0.0083	0.0083	0.0083	0.0143	0.0144	0.0144	0.0144	0.0145	0.0146	
	(0.0072-0.0094)	(0.0072-0.0094)	(0.0072-0.0094)	(0.0126-0.0161)	(0.0126-0.0161)	(0.0127-0.0161)	(0.0127-0.0161)	(0.0127-0.0162)	(0.0128-0.0164)	
Post-secondary	0.0099	0.01	0.0099	0.0162	0.0163	0.0162	0.0163	0.0164	0.0165	
	(0.0088-0.0112)	(0.0089-0.0113)	(0.0088-0.0112)	(0.015-0.0177)	(0.015-0.0178)	(0.015-0.0176)	(0.015-0.0177)	(0.0151-0.0179)	(0.0152-0.018)	
Secondary school	0.0161	0.016	0.0161	0.0254	0.0253	0.0254	0.0254	0.0255	0.0258	
	(0.0131-0.0189)	(0.0131-0.019)	(0.0132-0.0189)	(0.0213-0.0287)	(0.0212-0.0286)	(0.0214-0.0286)	(0.0215-0.0286)	(0.0214-0.0288)	(0.0215-0.0292)	
None of above	0.0197	0.0197	0.0196	0.0243	0.0243	0.0248	0.025	0.0243	0.0244	
	(0.0121-0.0301)	(0.0122-0.0302)	(0.0121-0.0299)	(0.0164-0.0366)	(0.0163-0.0367)	(0.017-0.0372)	(0.0175-0.0374)	(0.0163-0.0367)	(0.0162-0.037)	

# eTable 14: Overall performance (Brier scores) in the whole PLCO cohort

	Risk of death from lung cancer				Risk of developing lung cancer					
	UCLFull-D	UCL-D	LCDRAT	UCLFull-I	UCL-I	LCRAT	PLCOm2012*	LLP v2	LLP v3	
Ethnicity										
Asian	0.0054 (0.0029-0.0079)	0.0054 (0.0028-0.0079)	0.0054 (0.0028-0.008)	0.0089 (0.0057-0.0131)	0.0089 (0.0057-0.0131)	0.0088 (0.0056-0.0132)	0.0089 (0.0056-0.0132)	0.009 (0.0057-0.0132)	0.0089 (0.0056-0.0132)	
Black	0.0143 (0.0108-0.0177)	0.0144 (0.0109-0.0178)	0.0141 (0.0107-0.0175)	0.0222 (0.0179-0.0261)	0.0223 (0.0179-0.0261)	0.022 (0.0178-0.0256)	0.022 (0.0179-0.0256)	0.0224 (0.018-0.0263)	0.0227 (0.0183-0.0267)	
Other	0.0077 (0.0043-0.0111)	0.0077 (0.0042-0.0112)	0.0077 (0.0042-0.0111)	0.0114 (0.0076-0.0151)	0.0114 (0.0077-0.0151)	0.0114 (0.0076-0.0151)	0.0117 (0.008-0.0155)	0.0114 (0.0077-0.0151)	0.0115 (0.0076-0.0153)	
White	0.0086(0.008-0.0092)	0.0086 (0.008-0.0092)	0.0086 (0.008-0.0092)	0.0145 (0.0138-0.0153)	0.0146 (0.0138-0.0154)	0.0146 (0.0138-0.0154)	0.0146 (0.0139-0.0154)	0.0147 (0.0139-0.0155)	0.0148 (0.014-0.0156)	

Note that the LCDRAT, LCRAT, and PLCOm2012 models were developed in the control arm of the PLCO cohort. The PLCOm2012 was originally developed to predict 6-year risk of developing lung cancer. As Brier scores depend on prevalence, we present results for the PLCOm2012 against 5-year outcomes for the purposes of comparison







Net benefit across a range of thresholds of models predicting 5-year risk of death from lung cancer (a) and developing lung cancer (b) compared against USPSTF-2021 screening eligibility criteria in the PLCO cohort.

	Risk threshold (%)	Sensitivity	Specificity
Predicting 5-year risk of death from lung cancer			
UCLFull-D	0.74	0.849 (0.821-0.874)	0.574 (0.571-0.578)
USPSTF-2021	-	0.775 (0.746-0.809)	0.574 (0.570-0.578)
Predicting 5-year risk of developing lung cancer			
UCLFull-I	1.18	0.843 (0.822-0.863)	0.577 (0.573-0.580)
USPSTF-2021	-	0.777 (0.758-0.802)	0.576 (0.572-0.579)

eTable 15: Sensitivity and sensitivity of UCLFull-D and UCLFull-I at specified risk thresholds in the PLCO dataset

Risk thresholds set using a fixed population approach at a level that would screen an equivalent number as the USPSTF-2021 in the entire PLCO dataset.

### References

- 1. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z
- 2. National Lung Screening Trial Research Team, Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. *Radiology*. 2011;258(1):243-253. doi:10.1148/radiol.10091808
- 3. Oken MM, Hocking WG, Kvale PA, et al. Screening by Chest Radiograph and Lung Cancer Mortality. *JAMA*. 2011;306(17):1865. doi:10.1001/jama.2011.1591
- 4. Sperrin M, Martin GP, Sisk R, Peek N. Missing data should be handled differently for prediction than for description or causal explanation. *J Clin Epidemiol*. 2020;125:183-187. doi:10.1016/j.jclinepi.2020.03.028
- 5. Wilson S. *Miceforest*. Accessed February 24, 2022. https://github.com/AnotherSamWilson/miceforest
- 6. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med*. 2011;30(4):377-399. doi:10.1002/sim.4067
- Alaa A, van der Schaar M. AutoPrognosis: Automated Clinical Prognostic Modeling via Bayesian Optimization with Structured Kernel Learning. In: Dy J, Krause A, eds. Proceedings of the 35th International Conference on Machine Learning. Vol 80. Proceedings of Machine Learning Research. PMLR; 10--15 Jul 2018:139-148. https://proceedings.mlr.press/v80/alaa18b.html
- 8. Imrie F, Cebere B, McKinney EF, van der Schaar M. AutoPrognosis 2.0: Democratizing Diagnostic and Prognostic Modeling in Healthcare with Automated Machine Learning. *arXiv [csLG]*. Published online 21 October 2022. http://arxiv.org/abs/2210.12090
- 9. Freund Y, Schapire RE. A Decision-Theoretic Generalization of On-Line Learning and an Application to Boosting. *J Comput System Sci.* 1997;55(1):119-139. doi:10.1006/jcss.1997.1504
- 10. Scikit-learn. An AdaBoost Classifier. https://scikitlearn.org/stable/modules/generated/sklearn.ensemble.AdaBoostClassifier.html#sklearn. ensemble.AdaBoostClassifier
- 11. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python. *J Mach Learn Res.*
- Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: unbiased boosting with categorical features. In: Bengio S, Wallach H, Larochelle H, Grauman K, Cesa-Bianchi N, Garnett R, eds. *Advances in Neural Information Processing Systems*. Vol 31. Curran Associates, Inc.; 2018. https://proceedings.neurips.cc/paper/2018/file/14491b756b3a51daac41c24863285549-Paper.pdf
- 13. Yandex. CatBoost. https://catboost.ai/en/docs/
- 14. Ke G, Meng Q, Finley T, et al. LightGBM: A highly efficient gradient boosting decision tree. *Adv Neural Inf Process Syst.* 2017;30. Accessed January 10, 2023. https://proceedings.neurips.cc/paper/2017/hash/6449f44a102fde848669bdd9eb6b76fa-

Abstract.html

- 15. Microsoft. LightGBM. https://lightgbm.readthedocs.io/en/v3.3.4/index.html
- 16. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. *arXiv* [*csLG*]. Published online 9 March 2016. http://arxiv.org/abs/1603.02754
- 17. XGBoost. https://xgboost.readthedocs.io/en/stable/index.html
- Akiba T, Sano S, Yanase T, Ohta T, Koyama M. Optuna: A Next-generation Hyperparameter Optimization Framework. In: *Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining*. KDD '19. Association for Computing Machinery; 2019:2623-2631. doi:10.1145/3292500.3330701
- 19. Zhao Y, Wang X, Cheng C, Ding X. Combining Machine Learning Models and Scores using combo library. In: *Thirty-Fourth AAAI Conference on Artificial Intelligence*. ; 2020.
- 20. Therneau TM. A Package for Survival Analysis in R. https://CRAN.Rproject.org/package=survival
- 21. Harrel FE. *Regression Modelling Strategies*. https://cran.rproject.org/web/packages/rms/index.html
- 22. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. *N Engl J Med.* 2013;368(8):728-736. doi:10.1056/NEJMoa1211776
- 23. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. *JAMA*. 2016;315(21):2300-2311. doi:10.1001/jama.2016.6255
- 24. Field JK, Vulkan D, Davies MPA, Duffy SW, Gabe R. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. *Thorax*. 2021;76(2):161-168. doi:10.1136/thoraxjnl-2020-215158
- 25. Lundberg S, Lee SI. A Unified Approach to Interpreting Model Predictions. *arXiv* [csAI]. Published online 22 May 2017. http://arxiv.org/abs/1705.07874
- 26. Lundberg SM, Erion G, Chen H, et al. From Local Explanations to Global Understanding with Explainable AI for Trees. *Nat Mach Intell*. 2020;2(1):56-67. doi:10.1038/s42256-019-0138-9
- 27. Van Calster B, Vickers AJ, Pencina MJ, Baker SG, Timmerman D, Steyerberg EW. Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. *Med Decis Making*. 2013;33(4):490-501. doi:10.1177/0272989X12470757